Global Alpha Blockers Market – Industry Trends and Forecast to 2030

Alpha Blockers Market Analysis and Size

The alpha blocker market's huge growth is increased by the geriatric population and their related blood pressure. According to the WHO publication, around 1.13 billion people suffer from hypertension globally. Furthermore, it is expected that by 2025 the occurrence of hypertension increase to 29% from 26% in 2019. In this regards, alpha blockers are used to treat these patients.

Data Bridge Market Research analyses a growth rate in the alpha blockers market in the forecast period 2023-2030. Data Bridge Market Research analyses that the alpha blockers market is expected to reach USD 56.88 billion by 2030, which is USD 40 billion in 2022, and is expected to undergo a CAGR of 4.50% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Alpha Blockers Market Scope and Segmentation

Market Definition

The alpha blockers are the type of drugs used to treat high blood pressure, either alone or through combination therapy. These blockers are also used for treating several prostate problems. Alpha blockers help lower the blood pressure by maintaining the proper level of norepinephrine that tightens the muscle in the walls of blood vessels, which makes arteries and veins open and relaxed, which in turn improves the blood flow and lowers down he blood pressure.

Alpha Blockers Market Dynamics

Drivers

• Rising Usage in Pheochromocytoma Care

Alpha blockers have a major use in the setting of pre-operative pheochromocytoma care. They are also widely used off-label for post-traumatic stress disorder treatment. Numerous clinical studies have showed that the drug is most effective in patients in an upright position, where it can decrease diastolic and systolic pressures by up to 8%–10%. These drugs progressively decrease blood pressure combined with most drug classes and are the only anti-hypertensive drug class that enables improvement in plasma lipid profiles.

• Increasing Elderly Population

The increasing geriatric population is increasing the growth of the global alpha-blocker market. The aged population is the older population who are above the age of 60 years. As per the records of WHO, people having the age of 60 years and more will exceed the figure of 2 billion. This aged population is subjected to numerous chronic diseases and blood pressure related issues. Therefore, the growth in the geriatric population will positively impact the growth of the global alpha-blocker market.

Opportunities

• Increasing Prevalence of Hypertension

Sccording to the American College of Cardiology, older adults are typically undertreated for high blood pressure, even though they have the maximum occurrence of hypertension and the highest risk of CV morbidity and mortality (BP). According to the National Health and Nutrition Examination Survey (NHANES), hypertension affects almost 70% of persons over 65. As the population ages, it will continue to rise. In 2014, 15% of the US population was 65 years old, and that number is expected to rise to 20% by 2050. This will create more opportunities for the market growth.

• Growing Demand for Retail Pharmacies

The increase in the number of alpha blockers delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries can create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily available.

 Restraints/Challenges

• Side Effects of Alpha Blockers

There are numerous side effects associated with alpha blockers such as nausea, diarrhea or constipation, upset stomach, and erectile dysfunction when taking alpha blockers that impede the market growth.

This alpha blockers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the alpha blockers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Alpha Blockers Market Scope

The alpha blockers market is segmented on the basis of type, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Nonselective Alpha-Blockers
• Selective Alpha-1 Blockers
• Selective Alpha-2 Blockers

Application

• Hypertension
• Raynaud’s Disease
• Erectile Dysfunction
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Alpha Blockers Market Regional Analysis/Insights

The alpha blockers market is analyzed and market size insights and trends are provided by type, application, distribution channel and end-user as referenced above.

The major countries covered in the alpha blockers market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for alpha blockers market throughout the forecasted period due to increasing geriatric population. According to the publication of NCBI the population aged 65 years or more than will rise to 20.4% in 2050 from 13.3% in 2010 and growing occurrence of obesity. Europe accounts the second largest market share because of the increasing incidence of blood pressure and other related urinary tract symptoms in men.

Asia-Pacific dominates the market because of the growing demand of effective therapies and increasing awareness for prostate cancer and other urological disease.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Alpha Blockers Market Share Analysis

The alpha blockers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to alpha blockers market.

Key players operating in the alpha blockers market include:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Fresenius Kabi AG (Germany)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd (India)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)
• Zydus Group (India)
• Pfizer Inc (U.S.)
• Lupin (India)
• GSK Plc (U.K.)
• Glenmark Pharmaceuticals Inc (India)
• Amneal Pharmaceuticals (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Hovione (Portugal)
• Wockhardt (India)
• Apotex Inc (Canada)

SKU-60135